Also trades as: 0IFK.L (LSE) · $vol 0M
EDIT NASDAQ
Editas Medicine, Inc.
1W: -0.8%
1M: -7.0%
3M: -8.4%
YTD: +17.1%
1Y: -34.2%
3Y: -62.7%
5Y: -93.7%
$2.60
+0.20 (+8.33%)
After Hours: $2.54 (-0.06, -2.50%)
Weekly Expected Move ±10.8%
$2
$2
$2
$3
$3
Credit Risk of going bust: higher than 56% of companies Debt: 4.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.3%), Editas Medicine, Inc. would be worth roughly what it owes.
Total debt $15.5M against a stock market value of $368.6M.
Distance to default 4.53 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $7.8M (short-term plus half of long-term), stock volatility 81.2%; Altman Z'' -20.04. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.3%), Editas Medicine, Inc. would be worth roughly what it owes.
Total debt $15.5M against a stock market value of $368.6M.
Distance to default 4.53 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $7.8M (short-term plus half of long-term), stock volatility 81.2%; Altman Z'' -20.04. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-05-14
Earliest Filing
2024-10-04
Latest Filing
licensee: 2
customer: 1
partner: 1
Counterparties (Filed by EDIT)
4 relationshipsCompanies named in EDIT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | customer | Licensor of Cas9 gene-editing technology whose future license fees were purchased by the Company's subsidiary | 2024-10-04 | View |
| The Broad Institute, Inc. | — | licensee | Licensor whose obligations are deducted from payments received by the Company under the Vertex license agreement | 2024-10-04 | View |
| The President and Fellows of Harvard College | — | licensee | Licensor whose obligations are deducted from payments received by the Company under the Vertex license agreement | 2024-10-04 | View |
| Cowen and Company, LLC | — | partner | Sales agent for the common stock offering | 2021-05-14 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-08 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-05 | Earnings Release; Officer/Director Change; Exhibits | View | |
| 2026-06-18 | Shareholder Vote | View | |
| 2026-05-26 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-26 | Other Events | View | |
| 2026-05-26 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-05-14 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-04-07 | Accountant Change; Exhibits | View | |
| 2026-03-27 | Regulation FD; Other Events; Exhibits | View | |
| 2026-03-09 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-09 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-02 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-12 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-06-02 | Departure/Election of Directors; Appointment of Officers; Amendments to Articles of Incorporation or | View | |
| 2025-05-14 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-13 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR